Actual studies with contemporary multicenter cohorts [14,15,16,17,18,19,20,21,22], found suboptimal rates of use of secondary prevention therapies in high-risk patients with diabetes and atherosclerotic cardiovascular disease particularly with high-intensity statins and glucose-lowering therapies with proven cardiovascular benefit (such as SGLT-2 inhibitors). This evidence concerns the gene SLC5A2 and diabetes mellitus.